Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Response to omalizumab in patients with severe allergic asthma: A real-life study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Chronic rhinosinusitis in COPD: A prevalent but unrecognized comorbidity impacting health related quality of life

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The impact of dysfunctional breathing on the level of asthma control in difficult asthma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prognosis of COPD depends on severity of exacerbation history: A population-based analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Spousal bereavement after fibrotic interstitial lung disease: A qualitative study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Management of Ocular Manifestations of Atopic Dermatitis: A Consensus Meeting Using a Modified Delphi Process

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Chronic rhinosinusitis in COPD: A prevalent but unrecognized comorbidity impacting health related quality of life

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. High prevalence of exercise-induced stridor during Parkrun: a cross-sectional field-based evaluation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

INTRODUCTION: Omalizumab is a humanized monoclonal anti-IgE antibody, which is widely used for patients with severe uncontrolled asthma. Treatment with omalizumab is known to decrease the number of exacerbations and GETE score (Global Evaluation of Treatment Effectiveness) - but little is known about which patients benefit the most. Moreover, the time to discontinuation of the treatment with omalizumab has yet to be investigated. In this real-life study on a Danish population we explore these important issues.

METHOD: In a retrospective real-life study, 54 patients treated with omalizumab at a specialized outpatient asthma clinic were included. Change in GETE score, time to discontinuation of treatment and associated risk factors were analysed.

RESULTS: As a result of omalizumab treatment, most patients improved in GETE score from poor/worsening to excellent. Women were treated for a median time of 31 months (95% CI: 4.6-57.4) and approximately 50% of patients discontinued treatment after 500 days whilst, for men, 50% discontinued treatment after 1500 days. Eosinophil count above 300 cells/μL at treatment initiation was positively related to the discontinuation of omalizumab (HR 4.3 95%CI (1.22-15.28) p = 0.023).

CONCLUSION: In conclusion, female gender and an eosinophil count above 300 cells/μL may predict a better treatment response, leading to a shorter treatment time than the current guideline recommendation of maximum 48 months. Additionally, the GETE score improves with omalizumab. More real-life studies are needed to determine which patients will benefit the most from the treatment.

OriginalsprogEngelsk
TidsskriftRespiratory medicine
Vol/bind131
Sider (fra-til)109-113
Antal sider5
ISSN0954-6111
DOI
StatusUdgivet - okt. 2017

ID: 51921271